Validation of the prognostic and predictive value of class III beta tubulin (TUBB3) for adjuvant chemotherapy (ACT) in completely resected non-small cell lung cancer (R-NSCLC): results from four randomized trials

被引：0
|
作者：
Reiman, Tony [1 ]
Seve, Pascal [2 ]
Veillard, Anne-Sophie [3 ]
Soria, Jean-Charles [3 ]
Rosell, Rafael [4 ]
Taron, Miquel [4 ]
Graziano, Stephen [5 ]
Kratzke, Robert [8 ]
Seymour, Lesley [6 ]
Shepherd, Frances [9 ]
Pignon, Jean-Pierre [3 ]
Lai, Raymond [7 ]
机构：
[1] St Johns Hosp, St John, NB, Canada
[2] Hop Hotel Dieu, F-69288 Lyon, France
[3] Inst Gustave Roussy, Villejuif, France
[4] Catalan Inst Oncol, Badalona, Spain
[5] SUNY Syracuse, Syracuse, NY USA
[6] NCIC Clin Trials Grp, Kingston, ON, Canada
[7] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada
[8] Univ Minnesota, Minneapolis, MN USA
[9] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2009年 / 4卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S298 / S298
页数：1
相关论文
共 50 条
  • [11] High expression levels of class III β-tubulin in resected non-small cell lung cancer patients are predictive of improved patient survival after vinorelbine-based adjuvant chemotherapy
    Zhang, Yalei
    Yang, Haihong
    Liu, Jun
    Deng, Qiuhua
    He, Ping
    Lin, Yunen
    Jiang, Juhong
    Gu, Xia
    Mo, Mingcong
    Pan, Hui
    Xiong, Xinguo
    Qiu, Yuan
    He, Jianxing
    ONCOLOGY LETTERS, 2013, 6 (01) : 220 - 226
  • [12] Expression of ERCC1 and class III β-tubulin in resected non-small cell lung cancer and its correlation with platinum-based adjuvant chemotherapy
    Zhang, Shucai
    Li, Qi
    Zhang, Quan
    Wang, Jinghui
    Zhang, Haiqing
    Zhang, Zongde
    Wang, Qunhui
    Yang, Xinjie
    Cu, Yanfei
    Zhang, Hui
    INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2010, 25 (03): : 141 - 149
  • [13] Impact of hemoglobin (Hb) on outcomes of adjuvant chemotherapy (ACT) with cisplatin/vinorelbine in patients (pts) with completely resected non-small cell lung cancer (NSCLC) in JBR.10.
    Gauthier, I
    Ding, K
    Winton, T
    Shepherd, F
    Livingston, R
    Johnson, DH
    Rigas, JR
    Whitehead, M
    Graham, B
    Seymour, L
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 670S - 670S
  • [14] Expression of class III beta tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy
    Dumontet, C
    Seve, P
    Isaac, S
    Tredan, O
    Souquet, P
    Pacheco, Y
    Perol, M
    Lafanéchère, L
    Penet, A
    Peiller, E
    LUNG CANCER, 2005, 49 : S243 - S243
  • [15] Expression of excision repair cross-complementation group 1 and class III β-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer
    Okuda, Katsuhiro
    Sasaki, Hidefumi
    Dumontet, Charles
    Kawano, Osamu
    Yukiue, Haruhiro
    Yokoyama, Tomoki
    Yano, Motoki
    Fujii, Yoshitaka
    LUNG CANCER, 2008, 62 (01) : 105 - 112
  • [16] Cross-validation analysis of the prognostic significance of mucin expression in patients with resected non-small cell lung cancer (NSCLC) treated with adjuvant chemotherapy: results from IALT, JBR.10 and ANITA
    Graziano, Stephen L.
    Azougagh, Said
    Vollmer, Robin
    Kratzke, Robert
    Popper, Helmut
    Filipits, Martin
    Tsao, Ming
    Seymour, Lesley
    Rosell, Rafael
    Taron, Miquel
    Pignon, Jean-Pierre
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S506 - S506
  • [17] The Prognostic Role of the Class III β-Tubulin in Non-Small Cell Lung Cancer (NSCLC) Patients Receiving the Taxane/Vinorebine-Based Chemotherapy: A Meta-Analysis
    Yang, Yan-Long
    Luo, Xiu-Ping
    Xian, Lei
    PLOS ONE, 2014, 9 (04):
  • [18] Randomized clinical trial of adjuvant chemotherapy with docetaxel and carboplatin for completely resected stage IB to IIIA non-small cell lung cancer (NSCLC): Preliminary result of Chinese society of lung cancer (CSLC) protocol 0201
    Yang, X
    Wu, Y
    Chen, G
    Xu, L
    Gu, L
    Tang, P
    Zhu, Y
    Xiao, P
    Tang, J
    Xie, L
    LUNG CANCER, 2005, 49 : S97 - S97
  • [19] Results of the Randomized International Adjuvant Lung Cancer Trial (IALT): Cisplatin-based chemotherapy (CT) vs no CT in 1867 patients (pts) with resected non-small cell lung cancer (NSCLC).
    Le Chevalier, T
    JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) : 238S - 238S
  • [20] A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.
    Calvo, Virginia
    Domine, Manuel
    Sullivan, Ivana
    Gonzalez-Larriba, Jose-Luis
    Ortega, Ana Laura
    Bernabe, Reyes
    Sala, Maria Angeles
    Campos, Begona
    De Castro, Javier
    Martin-Martorell, Paloma
    Bosch-Barrera, Joaquim
    Mielgo, Xabier
    Vila, Laia
    Casal, Joaquin
    Ros, Silver
    Aguillo, Maite Martinez
    Padilla, Airam
    Sandiego, Sergio
    Machado, Jonathan Aires
    Provencio-Pulla, Mariano
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345